Science3 distinct publishers2 min readPublished
The FDA cleared daraxonrasib on Aug. 26 for patients whose chemotherapy has already failed. The median gain is 6.5 months, and the price has not been disclosed.
The Scientist · Science desk
Compiled by The ScientistSomething wrong?How this is made
The gain is a factor of 1.97 at the median [1], and it is a second-line number, so the clock starts after the disease has already outrun chemotherapy [3]. Put that against the baseline. Of patients diagnosed with metastatic pancreatic cancer between 2015 and 2021, about 97% were dead inside five years [10], which implies roughly 3% five-year survival for metastatic disease, against about 13% across all stages of the cancer with the worst five-year figure of any major type [11][2]. A median that crosses one year does not touch a five-year number. The tail might: Scientific American reports that some patients on the drug lived for years, which very few people with late-stage disease do [20].
Two effect sizes are circulating for the same 500-patient trial [4]. The oncologist writing in The Conversation puts the reduction in risk of death at 60% [7]. If survival were exponential, the ratio of medians would be the hazard ratio, and 6.7 divided by 13.2 gives 0.51, a 49% reduction [3]. The distance between 49% and 60% is not a rounding artifact. Either the curves separate more than the medians show, which would fit the long-survivor tail, or the two figures describe different endpoints or populations.
The mutation selection did less work than the framing implies. In the mutation-positive group the chemotherapy arm ran to 6.6 months and in the full trial to 6.7, while the daraxonrasib arm was 13.2 months in both [5][6][4]. Most enrolled patients carried the driver mutations [4], so this readout cannot show that testing identifies who benefits.
What actually got corrected is narrower than the slogan. The obstacle was a surface described as exceptionally smooth, lacking the molecular pockets a drug needs to grip [14]. Daraxonrasib never grips it: the pill binds cyclophilin A, a protein-folding helper, and that complex latches onto active KRAS and cuts the growth signal [15]. The failed assumption was about binding sites, not about the target.
Fewer patients stopped daraxonrasib for severe side effects than stopped chemotherapy, and they reported better quality of life with less pain [9], which for a population this sick is close to the whole point. Andrew Ko, a gastrointestinal oncologist at the University of California, San Francisco, told STAT it is the biggest development in pancreas cancer in decades [17]. That is a statement about sequencing options rather than cure rates. The regimen is two pills a day [2], and Revolution Medicines has not said what they cost, nor answered Scientific American's request for comment [18].
Ranked by verification strength, evidence, and original report placement.
A drug approved on Aug. 26, 2026, shuts down the key protein that drives pancreatic cancer, nearly doubling survival for patients with advanced disease; with the FDA's August 2026 approval, eligible patients can receive it for metastatic pancreatic cancer.
The medication is called daraxonrasib, is manufactured by Revolution Medicines, will be sold as Rasonque, and takes the form of a two-pills-a-day regimen.
The FDA approval makes the medication available to people with metastatic pancreatic cancer who have already been through chemotherapy; STAT describes it as a second-line treatment.
In the phase 3 trial, 500 patients, most of whom had specific cancer-driving gene mutations and all of whom had previously treated metastatic pancreatic cancer, were assigned to receive daraxonrasib or chemotherapy.
Patients with advanced pancreatic cancer who received Rasonque as a second-line treatment achieved a median overall survival of 13.2 months, compared with 6.7 months for patients offered standard chemotherapy.
In the patients with the specific cancer-driving mutations, median overall survival was 13.2 months in the daraxonrasib group versus 6.6 months in the chemotherapy group.
Follow any of these and your For You feed starts watching them — no settings page required.
Evidence-backed comparisons of source perspectives and observed adoption signals. Read the methodology
Which Builder, Operator, and Investor concerns the observed source mix emphasized—not a truth score.
Evidence, demonstrated adoption, hype gap, incentives, and confidence are assessed independently, each on its own current evidence. How these are measured.
Randomized phase 3 plus regulatory clearance, but key statistics unpublished in these sources
The survival result rests on a 500-patient randomized phase 3 trial that has read out and now carries an FDA approval, and three independent publishers report the same medians, including the subgroup/overall split. What is missing from the cluster is the hazard ratio, confidence intervals, the named mutation set and any peer-reviewed citation, and one relative-risk figure does not reconcile with the medians.
Approved and available, no real-world uptake or pricing data yet
Adoption is at the starting line: the label exists as of Aug. 26, 2026 and eligible second-line patients can now be prescribed the drug, but the cluster contains no prescription volumes, no launch metrics, no payer coverage and no price, and the manufacturer did not comment.
Real advance, modestly oversold by the framing
The underlying result is genuine and externally validated, so the gap is small rather than large. It is positive because 'breakthrough', 'transformative' and 'new era' language sits atop a 6.5-month median gain in the second line, an 86%-plus rash rate, an undisclosed price, and a 60% risk-of-death reduction that the reported medians imply should be nearer 49%.
Sponsor-shaped narrative with clinician commentary and no company accountability
The evidentiary chain runs largely through the sponsor: the phase 3 data were presented by Revolution Medicines, the commercial framing benefits the company, and the company declined to engage on price. Commentary comes from clinicians with professional stakes in the field, including a gastrointestinal oncologist who runs early-phase trials and writes the piece forecasting more KRAS trials, and no dissenting or payer voice appears in any source.
High confidence on the core facts, low on economics and durability
Date, sponsor, brand name, label setting and both medians are corroborated across three independent publishers, which supports strong confidence in the factual spine. Confidence is held down by the unreconciled risk-reduction statistic, the absence of pricing and access information, and the fact that toxicity and mechanism detail rest on a single source.
product
Enhanced Games' $62M quarter puts a price on buying legitimacy1 distinct publisher
science
97% of the record menthol-ban comments were form letters, Rutgers audit of all 246,808 finds1 distinct publisher
science
Psilocybin's 'oneness' now has a brain-network correlate, and it was found by sorting people on self-report1 distinct publisher
leadership
Detection got faster than tracing, and the produce buyer now owns the recall1 distinct publisher
Distinct publishers with included, body-backed reporting in this cluster.
1 article · August 26, 2026
1 article · August 26, 2026
1 article · August 26, 2026